A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
about
Current clinical immunotherapeutic approaches for head and neck cancerAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesTargeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for TherapyPerspectives for therapeutic HPV vaccine developmentNovel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaTrial Watch: Peptide-based anticancer vaccines.MAGE-A3: an immunogenic target used in clinical practice.Current state in the development of candidate therapeutic HPV vaccinesVaccination Expectations in HNSCC.Recent progress in GM-CSF-based cancer immunotherapy.Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neckCpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinomaGenomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma.Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.
P2860
Q26745411-12F8A1AE-67F4-4A0D-8EB0-49EB74EF975AQ26774312-43C97338-C506-4F77-8111-9DD3B8C8D390Q26824925-890DEFED-EB33-4373-9C60-B6602477BDD4Q28069272-81E7ACBE-E970-4AAC-B453-957EB8AD6824Q28071998-6D549FEB-3351-4536-8BA4-493962F5D02BQ34483345-7981C875-6C72-43C9-A237-F7589A4F595AQ38534721-0D0C775B-6307-4797-B921-0832B9204DDEQ38743922-34ACD0C1-CCBA-48FE-B280-F266F9C915EAQ38971587-B34EFC34-B13F-4F7D-A2FC-C34DA79D9C29Q39183386-D3DB327F-A523-4F09-BDA8-30AD8F0D540FQ39999283-A09425A7-43D3-49A9-B40A-47E9F6079D6AQ40724264-02ED859A-8E86-43E3-95C5-291EF5FD6D43Q41198162-9AAA5F55-22AC-4569-9DE6-98D490719EEDQ45408645-6D8BA668-5D7C-48F5-8526-D5C9418C55C6Q52672798-3DDFEE02-4E29-460C-86D7-31D93ADCDEEDQ54256927-AEFCE02A-4792-4986-94A7-9BBFE6B47723
P2860
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase I dose escalation tria ...... of the head and neck (SCCHN).
@ast
A phase I dose escalation tria ...... of the head and neck (SCCHN).
@en
type
label
A phase I dose escalation tria ...... of the head and neck (SCCHN).
@ast
A phase I dose escalation tria ...... of the head and neck (SCCHN).
@en
prefLabel
A phase I dose escalation tria ...... of the head and neck (SCCHN).
@ast
A phase I dose escalation tria ...... of the head and neck (SCCHN).
@en
P2093
P2860
P1476
A phase I dose escalation tria ...... a of the head and neck (SCCHN)
@en
P2093
Ann Zimrin
Dan P Zandberg
Jeffrey S Wolf
John C Papadimitriou
Joshua E Lubek
Kevin J Cullen
Martin J Edelman
Mohan Suntharalingam
P2860
P2888
P304
P356
10.1007/S00262-014-1640-X
P577
2014-12-24T00:00:00Z